MDM2 and neoplasm: This therapeutic strategy could potentially be applied to the roughly 50% of tumors that are p53WT, and preclinical studies with small molecule MDM2 inhibitors have yielded promising reductions in tumor growth both in vitro and in vivo [13, 14].